OTCMKTS:RLMDRelmada Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Relmada Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $46.18 +1.11 (+2.46 %) (As of 05/28/2020 04:00 PM ET) Add Compare Share Today's Range$43.59Now: $46.18▼$47.1550-Day Range$33.29MA: $39.67▼$47.3152-Week Range$6.60Now: $46.18▼$52.22Volume64,518 shsAverage Volume132,809 shsMarket Capitalization$701.84 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing drugs to treat central nervous system (CNS) diseases and other disorders in the United States. Its lead product candidate, d-Methadone, is being developed as a rapidly acting, oral agent for the treatment of depression, neuropathic pain, and/or other potential CNS pathological conditions. The company is also developing LevoCap ER, an extended release, abuse deterrent, and proprietary formulation of the opioid analgesic levorphanol for the treatment of pain; BuTab, a formulation of oral, modified release buprenorphine for chronic pain and opioid dependence; and MepiGel, a proprietary topical dosage form of the local anesthetic mepivacaine for the treatment of painful peripheral neuropathies, such as painful diabetic neuropathy, postherpetic neuralgia, and painful HIV-associated neuropathy. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in New York, New York.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingRelmada Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $69.25, Relmada Therapeutics has a potential upside of 50.0% from its current price of $46.18.Amount of Analyst CoverageRelmada Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 2.8 Community Rank Outperform VotesRelmada Therapeutics has received 115 “outperform” votes. (Add your “outperform” vote.)Underperform VotesRelmada Therapeutics has received 92 “underperform” votes. (Add your “underperform” vote.)Community SentimentRelmada Therapeutics has received 55.56% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Relmada Therapeutics and other stocks. Vote “Outperform” if you believe RLMD will outperform the S&P 500 over the long term. Vote “Underperform” if you believe RLMD will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldRelmada Therapeutics does not currently pay a dividend.Dividend GrowthRelmada Therapeutics does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Relmada Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.20% of the stock of Relmada Therapeutics is held by insiders. Previous Next 0.0 Earnings and Valuation Previous Next Analyst Opinion: 3.5Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.26 out of 5 stars Industry, Sector and Symbol Stock Exchange OTCMKTS Industry Drug Manufacturers—Specialty & Generic Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:RLMD Previous Symbol CUSIPN/A CIK1553643 Webwww.relmada.com Phone646-876-3459Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees6 Outstanding Shares15,198,000Market Cap$701.84 million Next Earnings DateN/A OptionableNot Optionable OTC:RLMD Rates by TradingView Receive RLMD News and Ratings via Email Sign-up to receive the latest news and ratings for RLMD and its competitors with MarketBeat's FREE daily newsletter. Relmada Therapeutics (OTCMKTS:RLMD) Frequently Asked Questions How has Relmada Therapeutics' stock been impacted by COVID-19 (Coronavirus)? Relmada Therapeutics' stock was trading at $40.20 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, RLMD shares have increased by 14.9% and is now trading at $46.18. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Relmada Therapeutics? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Relmada Therapeutics in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Relmada Therapeutics. How were Relmada Therapeutics' earnings last quarter? Relmada Therapeutics Inc (OTCMKTS:RLMD) issued its earnings results on Tuesday, November, 13th. The company reported ($0.27) earnings per share (EPS) for the quarter. View Relmada Therapeutics' earnings history. What price target have analysts set for RLMD? 4 equities research analysts have issued 1-year target prices for Relmada Therapeutics' shares. Their forecasts range from $63.00 to $75.00. On average, they anticipate Relmada Therapeutics' share price to reach $69.25 in the next year. This suggests a possible upside of 50.0% from the stock's current price. View analysts' price targets for Relmada Therapeutics. Has Relmada Therapeutics been receiving favorable news coverage? News stories about RLMD stock have been trending somewhat positive this week, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Relmada Therapeutics earned a news impact score of 1.4 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the next few days. View the latest news aboutRelmada Therapeutics. Who are some of Relmada Therapeutics' key competitors? Some companies that are related to Relmada Therapeutics include Medipharm Labs (LABS), Khiron Life Sciences (KHRN), 48North Cannabis (NRTH), Willow Biosciences (WLLW), National Access Cannabis (META), Cronos Australia (CAU), Two Rivers Water & Farming (MJNE), Kali (RDGL), AAC Technologies (ABSCF), Abattis Bioceuticals (ATT), AgraFlora Organics International (AGRA), AgraFlora Organics International (AGFAF), Avicanna (PDDPF), Benitec Biopharma (BLT) and Biome Grow (BIOIF). View all competitors. What other stocks do shareholders of Relmada Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Relmada Therapeutics investors own include Verizon Communications (VZ), Alteryx (AYX), Enterprise Products Partners (EPD), Vertex Pharmaceuticals (VRTX), Advanced Micro Devices (AMD), Intel (INTC), Okta (OKTA), Energy Transfer LP Unit (ET), IBM (IBM) and JPMorgan Chase & Co. (JPM). Who are Relmada Therapeutics' key executives? Relmada Therapeutics' management team includes the following people: Dr. Sergio Traversa M.B.A., Pharm.D., PharmD, MBA, CEO & Director (Age 60, Pay $678.23k)Mr. Maged S. Shenouda M.B.A., R.Ph., R.Ph, MBA, Chief Financial Officer (Age 56, Pay $33.5k)Mr. Charles S. Ence CPA, M.B.A., Chief Accounting & Compliance Officer (Age 55, Pay $290.36k)Ms. Gina DiGuglielmo, VP & Head of Clinical OperationsDr. Thomas C. Wessel, Exec. VP and Head of R&D (Age 64) What is Relmada Therapeutics' stock symbol? Relmada Therapeutics trades on the OTCMKTS under the ticker symbol "RLMD." Who are Relmada Therapeutics' major shareholders? Relmada Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include RA Capital Management L.P. (9.40%), VR Adviser LLC (5.74%), BlackRock Inc. (3.26%), Parsons Capital Management Inc. RI (2.90%), Invesco Ltd. (1.81%) and Geode Capital Management LLC (0.73%). View institutional ownership trends for Relmada Therapeutics. Which major investors are selling Relmada Therapeutics stock? RLMD stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Bank of New York Mellon Corp, Weiss Multi Strategy Advisers LLC, Invesco Ltd., Meyer Handelman Co., and UBS Group AG. View insider buying and selling activity for Relmada Therapeutics. Which major investors are buying Relmada Therapeutics stock? RLMD stock was purchased by a variety of institutional investors in the last quarter, including VR Adviser LLC, RA Capital Management L.P., BlackRock Inc., Parsons Capital Management Inc. RI, Ikarian Capital LLC, Soleus Capital Management L.P., Geode Capital Management LLC, and State Street Corp. View insider buying and selling activity for Relmada Therapeutics. How do I buy shares of Relmada Therapeutics? Shares of RLMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Relmada Therapeutics' stock price today? One share of RLMD stock can currently be purchased for approximately $46.18. How big of a company is Relmada Therapeutics? Relmada Therapeutics has a market capitalization of $701.84 million. Relmada Therapeutics employs 6 workers across the globe. What is Relmada Therapeutics' official website? The official website for Relmada Therapeutics is www.relmada.com. How can I contact Relmada Therapeutics? The company can be reached via phone at 646-876-3459. This page was last updated on 5/28/2020 by MarketBeat.com Staff
